Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Medtech
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
Multimedia
Blog
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Breadcrumb
Home
Vantage
Articles
Insights
Vantage Data Points
Vantage Data Points
Evaluate
March 24, 2021
2021’s medtech M&A ticks up further
January 11, 2021
Datapoint: the UK’s biggest biotech buyouts
November 04, 2019
Share price movers – October 2019
September 24, 2019
Launch figures show a tale of two Car-Ts
September 16, 2019
Dropping the Bace
September 05, 2019
Share price movers – August 2019
August 16, 2019
Biopharma's least novel indications
August 15, 2019
Biopharma's biggest sellers – looking forward
August 06, 2019
Share price movers – July 2019
July 16, 2019
Datapoint: Cell and gene therapy trials
July 11, 2019
Venture funding distribution – medtech and biopharma
Load More
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
May 15, 2023
Pharma’s Biggest Spenders 2022 Infographic
May 03, 2023
Gene Editing: Overhyped or Unstoppable Tide?
